Anli Xirong

Elixiron Immunotherapeutics (Shanghai) Limited, established in Shanghai with a global perspective, is an innovative drug development company specializing in immunotherapy driven by translational medicine. Its current R&D pipeline includes multiple new drug projects for the treatment of cancer, neurological diseases, chronic hepatitis B, and autoimmune diseases. In preclinical trials, EI-1071 demonstrated high affinity and selectivity in inhibiting and eliminating a specific type of microglia in the nervous system, effectively blocking neuroinflammatory responses that drive disease progression. This slows nerve damage, aids in neural repair, and achieves therapeutic effects in improving cognitive function. It holds potential for treating various neurological disorders such as stroke, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and Alzheimer’s disease. Its Phase 1 clinical trial received funding from the Alzheimer's Association (USA) in August of the previous year.